Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Eli Lilly and Company
With
Loxo Oncology, Inc.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Participants with histologically confirmed B-cell malignancy including:
* Mantle cell lymphoma (MCL) treated with a prior Bruton's tyrosine kinase (BTK) inhibitor containing regimen;
* CLL/SLL treated with a prior BTK inhibitor containing regimen;
* Other types of B-cell NHL
All participants must have disease requiring treatment, for CLL/SLL participants, at least 1 indication for treatment consistent with IWCLL 2018 criteria is required
Eastern Cooperative Oncology Group 0-2
Adequate hematologic status, coagulation, hepatic and renal function
You may not be if
Lack of adequate wash-out period for investigational agent or anticancer therapy, major surgery, and radiotherapy prior to the first dose of study treatment
Participants requiring therapeutic anticoagulation with warfarin
Known central nervous system (CNS) involvement by systemic lymphoma. Primary CNS lymphoma is excluded
Significant cardiovascular disease
Prolongation of the QT interval
Test positive for human immunodeficiency virus (HIV)
Current treatment with certain strong cytochrome P450 3A4 (CYP450 3A4) inhibitors or inducers and/or strong p-glycoprotein (P-gp) inhibitors
Pregnancy or lactation
Active second malignancy
Prior treatment with LOXO-305
Known hypersensitivity to any component or excipient of LOXO-305